Literature DB >> 30410216

Glecaprevir/pibrentasvir for hepatitis C.

.   

Abstract

Entities:  

Keywords:  Maviret; glecaprevir/pibrentasvir; hepatitis C

Year:  2018        PMID： 30410216      PMCID： PMC6202291          DOI： 10.18773/austprescr.2018.050

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  8 in total

1.  Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Authors:  Tarik Asselah; Kris V Kowdley; Neddie Zadeikis; Stanley Wang; Tarek Hassanein; Yves Horsmans; Massimo Colombo; Filipe Calinas; Humberto Aguilar; Victor de Ledinghen; Parvez S Mantry; Christophe Hezode; Rui Tato Marinho; Kosh Agarwal; Frederik Nevens; Magdy Elkhashab; Jens Kort; Ran Liu; Teresa I Ng; Preethi Krishnan; Chih-Wei Lin; Federico J Mensa
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-22       Impact factor: 11.382

2.  Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.

Authors:  Stefan Zeuzem; Graham R Foster; Stanley Wang; Armen Asatryan; Edward Gane; Jordan J Feld; Tarik Asselah; Marc Bourlière; Peter J Ruane; Heiner Wedemeyer; Stanislas Pol; Robert Flisiak; Fred Poordad; Wan-Long Chuang; Catherine A Stedman; Steven Flamm; Paul Kwo; Gregory J Dore; Gladys Sepulveda-Arzola; Stuart K Roberts; Ruth Soto-Malave; Kelly Kaita; Massimo Puoti; John Vierling; Edward Tam; Hugo E Vargas; Rafi Bruck; Francisco Fuster; Seung-Woon Paik; Franco Felizarta; Jens Kort; Bo Fu; Ran Liu; Teresa I Ng; Tami Pilot-Matias; Chih-Wei Lin; Roger Trinh; Federico J Mensa
Journal:  N Engl J Med       Date:  2018-01-25       Impact factor: 91.245

3.  Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Authors:  Xavier Forns; Samuel S Lee; Joaquin Valdes; Sabela Lens; Reem Ghalib; Humberto Aguilar; Franco Felizarta; Tarek Hassanein; Holger Hinrichsen; Diego Rincon; Rosa Morillas; Stefan Zeuzem; Yves Horsmans; David R Nelson; Yao Yu; Preethi Krishnan; Chih-Wei Lin; Jens J Kort; Federico J Mensa
Journal:  Lancet Infect Dis       Date:  2017-08-14       Impact factor: 25.071

4.  Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

Authors:  Paul Y Kwo; Fred Poordad; Armen Asatryan; Stanley Wang; David L Wyles; Tarek Hassanein; Franco Felizarta; Mark S Sulkowski; Edward Gane; Benedict Maliakkal; J Scott Overcash; Stuart C Gordon; Andrew J Muir; Humberto Aguilar; Kosh Agarwal; Gregory J Dore; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa
Journal:  J Hepatol       Date:  2017-04-13       Impact factor: 25.083

5.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

Authors:  Edward Gane; Eric Lawitz; David Pugatch; Georgios Papatheodoridis; Norbert Bräu; Ashley Brown; Stanislas Pol; Vincent Leroy; Marcello Persico; Christophe Moreno; Massimo Colombo; Eric M Yoshida; David R Nelson; Christine Collins; Yang Lei; Matthew Kosloski; Federico J Mensa
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

6.  Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.

Authors:  Fred Poordad; Franco Felizarta; Armen Asatryan; Mark S Sulkowski; Robert W Reindollar; Charles S Landis; Stuart C Gordon; Steven L Flamm; Michael W Fried; David E Bernstein; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa
Journal:  Hepatology       Date:  2017-04-10       Impact factor: 17.425

7.  Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.

Authors:  David Wyles; Fred Poordad; Stanley Wang; Laurent Alric; Franco Felizarta; Paul Y Kwo; Benedict Maliakkal; Kosh Agarwal; Tarek Hassanein; Frank Weilert; Samuel S Lee; Jens Kort; Sandra S Lovell; Ran Liu; Chih-Wei Lin; Tami Pilot-Matias; Preethi Krishnan; Federico J Mensa
Journal:  Hepatology       Date:  2018-01-04       Impact factor: 17.425

8.  Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.

Authors:  Fred Poordad; Stanislas Pol; Armen Asatryan; Maria Buti; David Shaw; Christophe Hézode; Franco Felizarta; Robert W Reindollar; Stuart C Gordon; Stephen Pianko; Michael W Fried; David E Bernstein; Joel Gallant; Chih-Wei Lin; Yang Lei; Teresa I Ng; Preethi Krishnan; Sarah Kopecky-Bromberg; Jens Kort; Federico J Mensa
Journal:  Hepatology       Date:  2018-01-30       Impact factor: 17.425
  8 in total
  1 in total

1.  Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.

Authors:  Hsu-Heng Yen; Pei-Yuan Su; Ya-Huei Zeng; I-Ling Liu; Siou-Ping Huang; Yu-Chun Hsu; Yang-Yuan Chen; Chia-Wei Yang; Shun-Sheng Wu; Kun-Ching Chou
Journal:  PLoS One       Date:  2020-08-13       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.